OS - OneStream, Inc. Class A Common Stock News

Discover

OS

OneStream, Inc. Class A Common Stock

24.00

3 x 23.99

2 x 30.72

bid

ask

+

0.00

0.00%

09:30 AM

Ytd	30.58%
1y	5.82%

24.00

day range

24.00

16.51

52 week range

29.66

Open	24.00	Prev Close	24.00	Low	24.00	High	24.00	Mkt Cap	2.40B
Vol	2.66M	Avg Vol	4.52M	EPS	-0.28	P/E	-85.71	Forward P/E	52.46
Beta	1.99	Short Ratio	4.59	Inst. Own	89.17%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	05-07	50-d Avg	23.65	200-d Avg	21.78	1yr Est	24.00

OS News

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α

Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2Î

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers

Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improv

Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatu

Gabelli Funds LLC Makes New Investment in OneStream, Inc. $OS

defenseworld.net

Gabelli Funds LLC Makes New Investment in OneStream, Inc. $OS

Gabelli Funds LLC bought a new stake in shares of OneStream, Inc. (NASDAQ: OS) during the first quar

Annis Gardner Whiting Capital Advisors LLC Grows Position in OneStream, Inc. $OS

defenseworld.net

Annis Gardner Whiting Capital Advisors LLC Grows Position in OneStream, Inc. $OS

Annis Gardner Whiting Capital Advisors LLC increased its stake in shares of OneStream, Inc. (NASDAQ:

Advanced Polymer Coatings (APC) Collaborates with Albert Invent to Scale the Future of Modern R&D Infrastructure for Coatings

businesswire.com

Advanced Polymer Coatings (APC) Collaborates with Albert Invent to Scale the Future of Modern R&D In

AVON, Ohio & OAKLAND, Calif.--(BUSINESS WIRE)--Advanced Polymer Coatings (APC), a global leader in p

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 4

Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 4

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced new data from two studies evaluating epcorita

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel$

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demon

New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demon

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr

Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evalu

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Ben

[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company

WilliamsMarston's AIT Consulting Services Wins OneStream AI Excellence Award

businesswire.com

WilliamsMarston's AIT Consulting Services Wins OneStream AI Excellence Award

BOSTON--(BUSINESS WIRE)--WilliamsMarston, a national leader in complex accounting, tax, technology,

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Ad

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% i

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Comp

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal C

[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed progression-free and overall survival

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or d

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or d

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic

[url="]Pfizer Inc. [/url](NYSE: PFE) today announced detailed results from the pivotal Phase 3 TALAP

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patie

Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Pr

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evalu

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as

RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as

Earnings Scheduled For February 26, 2026

Earnings Scheduled For February 26, 2026

SanDisk To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday

SanDisk To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday

12 Information Technology Stocks Moving In Tuesday's Intraday Session

12 Information Technology Stocks Moving In Tuesday's Intraday Session

Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday

Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Movi

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket

Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket

Dropbox, Globus Medical, Expedia, Genpact And Other Big Stocks Moving Higher On Friday

Dropbox, Globus Medical, Expedia, Genpact And Other Big Stocks Moving Higher On Friday

12 Information Technology Stocks Moving In Friday's Intraday Session

Earnings Scheduled For November 6, 2025

Earnings Scheduled For November 6, 2025

Earnings Scheduled For August 7, 2025

Earnings Scheduled For May 8, 2025

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Earnings Scheduled For February 11, 2025